C1QTNF9 and pulmonary arterial hypertension: Our research team demonstrated previously that CTRP9 ameliorated the pathological progression of PAH by improving the inflammatory response and attenuating endothelial cell survival, as well as by regulating hypoxia-mediated human pulmonary artery SMC proliferation, apoptosis, and migration in vitro [13, 14].